-
Personalized Immunotherapy Earns FDA RMAT Status in Advanced Ovarian Cancer
07 Feb 2025 00:52 GMT
… immunotherapy, as a maintenance treatment for patients with newly diagnosed … RMAT designation, developers are eligible to facilitate more frequent FDA interactions and … #47;4yr3mk8s
A trial of Vigil for participants with ovarian cancer (VITAL). ClinicalTrials …
-
FDA Grants Gemogenovatucel-T RMAT Status in Advanced Ovarian Cancer
06 Feb 2025 23:46 GMT
… treatment for newly diagnosed, advanced stage IIIB/IV ovarian cancer … our [gemogenovatucel-T] development efforts as we …
REFERENCES
Gradalis secures FDA regenerative medicine advanced therapy …
A trial of vigil for participants with ovarian cancer (VITAL …
-
Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
06 Feb 2025 17:11 GMT
… for treating recurrent or platinum-resistant ovarian cancer, warranting … drug interruption or discontinuation. In the KEYNOTE-775 trial … blood pressure control despite medication: systolic > … inhibitors in the treatment of ovarian cancer: current state and …
-
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
06 Feb 2025 13:00 GMT
… -stage pharmaceutical company dedicated to developing stenoparib— … development of stenoparib toward FDA approval in advanced ovarian cancer. … regulatory approval, this trial is also designed … drug. By screening patients before treatment, and only treating …
-
‘A prisoner in my own body’: The indescribable toll of endometriosis and ovarian cancer
06 Feb 2025 01:14 GMT
… most dreaded C diagnosis: ovarian cancer.
I had what the … became despondent.
I progressively developed this unusual hip pain and … therapy and beginning additional hormone treatment for PMDD, but even … its shades!
During my ovarian cancer journey, I felt like …
-
Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer
05 Feb 2025 22:53 GMT
… treatment of patients with newly diagnosed, advanced, stage IIIB/IV ovarian cancer … gemogenovatucel-T] development efforts as … Gradalis secures FDA regenerative medicine … ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial …
-
Could the Birth Control Pill Reduce Ovarian Cancer Risk?
05 Feb 2025 18:13 GMT
… birth control pills can help lower the risk of ovarian cancer.
Ovarian cancer is known … appear until advanced stages when treatment is more difficult.
Researchers used … of monitoring, about 14-hundred developed ovarian cancer.
But women who had ever …
-
Ovarian Cancer Drug Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation
05 Feb 2025 16:20 GMT
… Inc., announced that the FDA has granted the company … VITAL trial. Vigil is being developed as a maintenance treatment … women with HRP ovarian cancer, current treatment options are even less … special offers
from American Pharmaceutical Review – all delivered …
-
The Pill Protects Against Ovarian Cancer, Study Says
05 Feb 2025 12:38 GMT
Key Takeaways
The Pill can help ward off ovarian cancer
Women who have used … 13 years, 1,441 women developed ovarian cancer. Researchers dug deep to figure … diverse characteristics related to health, medication use, diet and lifestyle, physical …
-
Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
05 Feb 2025 12:00 GMT
… the U.S. Food and Drug Administration (FDA) has granted Gradalis’ personalized … 2b VITAL trial. Vigil is being developed as a maintenance treatment for women … . For women with HRP ovarian cancer, current treatment options are even less effective …
About
© 1995-2025